Imzokitug
Based on 1 Customer Validation
Imzokitug (BMS-986340; CCR8.50) is a CCR8 binding agent. Imzokitug inhibits tumor growth in syngeneic tumors by blocking CCR8 and depleting tumor-resident CCR8+ Treg cells, while increasing CD4+/CD8+ T cell proliferation and upregulating PD-1. Imzokitug can be used for cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 2883771-61-5
- Masse moléculaire:145.863 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
CCR8 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (hCCR8 (v2) knockin expressing full-length human CCR8)[2]
-
Dosage:2 mg/kg; 10 mg/kg
-
Administration:i.p.; repeated dosing to at least 6 doses
-
Result:Led to ~38% TGI at 2 mg/kg and ~50% TGI at 10 mg/kg in the MC38 tumor model.
Tumor-resident CCR8+ Treg populations decreased, and CD4+/CD8+ T cell proliferation and PD-1 upregulation in CD4+/CD8+ T cells were observed 24 h post 6th dose.
- Naïve CD4+ T-cell subset differentiation/polarization
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Patient-Derived Orthotopic Xenograft (PDOX)
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Research Protocol for Cancer Immunology
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Patient-Derived Xenograft (PDX)
- Subcutaneous Cell-Line-Derived Xenograft
- MTT Cell Proliferation Assay
- Orthotopic Cell-Line Xenograft
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CCR8 (red) with Imzokitug (HY-P991001). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS No. 2883771-61-5
-
Accession P51685
-
Synonyms BMS-986340; CCR8.50
-
Masse moléculaire 145.863 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
IgG1-kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
98%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)